81_FR_42845 81 FR 42719 - National Cancer Institute; Notice of Closed Meetings

81 FR 42719 - National Cancer Institute; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 126 (June 30, 2016)

Page Range42719-42720
FR Document2016-15447

Federal Register, Volume 81 Issue 126 (Thursday, June 30, 2016) 
[Federal Register Volume 81, Number 126 (Thursday, June 30, 2016)]
[Notices]
[Pages 42719-42720]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-15447]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Member Conflict SEP.
    Date: July 6, 2016.

[[Page 42720]]

    Time: 10:30 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute Shady Grove, 9609 Medical 
Center Drive, Room 7W602, Rockville, MD 20850, (Telephone Conference 
Call).
    Contact Person: Delia Tang, MD, Scientific Review Officer, 
Research Programs Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9609 Medical Center Drive, Room 
7W602, Rockville, MD 20850 240-276-7684, tangd@mail.nih.gov.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: June 24, 2016.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-15447 Filed 6-29-16; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 81, No. 126 / Thursday, June 30, 2016 / Notices 42719 Background Information on and Transplantation Research; 93.856, simultaneously detected by each NICEATM: NICEATM conducts data Microbiology and Infectious Diseases respective objective lens along a analyses, workshops, independent Research, National Institutes of Health, HHS) respective longitudinal axis. Including validation studies, and other activities Dated: June 24, 2016. multiple lenses will improve the to assess new, revised, and alternative Natasha M. Copeland, penetration depth and at the same time test methods and strategies. NICEATM Program Analyst, Office of Federal Advisory decrease the loss of detail because of also provides support for the Committee Policy. scattering. The system also can Interagency Coordinating Committee on [FR Doc. 2016–15443 Filed 6–29–16; 8:45 am] overcome losses in spatial resolution the Validation of Alternative Methods BILLING CODE 4140–01–P because of the scattering of the (ICCVAM). The ICCVAM Authorization excitation and emission light. Act of 2000 (42 U.S.C. 285l–3) provides Potential Commercial Applications: authority for ICCVAM and NICEATM in DEPARTMENT OF HEALTH AND —High resolution multi-photon the development of alternative test HUMAN SERVICES microscopy methods. Information about NICEATM —Deep tissue visualization and ICCVAM is found at http:// National Institutes of Health —Competitive Advantages: ntp.niehs.nih.gov/go/niceatm and —Improved signal-to-noise ratio http://ntp.niehs.nih.gov/go/iccvam. Government-Owned Inventions; —improved spatial resolution Availability for Licensing —Development Stage: Dated: June 24, 2016. John R. Bucher, AGENCY: National Institutes of Health, • Prototype Associate Director, National Toxicology HHS. Inventors: Yicong Wu (NIBIB), Hari Program. ACTION: Notice. Shroff (NIBIB), Jianyong Tang (NIAID), [FR Doc. 2016–15444 Filed 6–29–16; 8:45 am] Ronald Germain (NIAID). SUMMARY: The inventions listed below Intellectual Property: HHS Reference BILLING CODE 4140–01–P are owned by an agency of the U.S. No. E–229–2015/0; U.S. Provisional Government and are available for Patent Application 62/210,153 filed DEPARTMENT OF HEALTH AND licensing in the U.S. in accordance with August 26, 2015. HUMAN SERVICES 35 U.S.C. 209 and 37 CFR part 404 to Licensing Contact: Michael achieve expeditious commercialization Shmilovich, Esq, CLP; 301–435–5019; National Institutes of Health of results of federally-funded research shmilovm@mail.nih.gov. and development. National Institute of Allergy and Dated: June 24, 2016. FOR FURTHER INFORMATION CONTACT: Infectious Diseases; Notice of Closed Michael Shmilovich, Licensing information may be obtained Meeting by emailing the indicated licensing Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Pursuant to section 10(d) of the contact at the National Heart, Lung, and Office of Technology Transfer and Federal Advisory Committee Act, as Blood, Office of Technology Transfer Development. amended (5 U.S.C. App.), notice is and Development Office of Technology [FR Doc. 2016–15441 Filed 6–29–16; 8:45 am] hereby given of the following meeting. Transfer, 31 Center Drive Room 4A29, BILLING CODE 4140–01–P The meeting will be closed to the MSC2479, Bethesda, MD 20892–2479; public in accordance with the telephone: 301–402–5579. A signed provisions set forth in sections Confidential Disclosure Agreement may DEPARTMENT OF HEALTH AND 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., be required to receive any unpublished HUMAN SERVICES as amended. The grant applications and information. the discussions could disclose SUPPLEMENTARY INFORMATION: National Institutes of Health confidential trade secrets or commercial Technology description follows. property such as patentable material, National Cancer Institute; Notice of Multi-Photon Microscopy System Closed Meetings and personal information concerning Configured for Multiview Non-Linear individuals associated with the grant Optical Imaging Pursuant to section 10(d) of the applications, the disclosure of which Federal Advisory Committee Act, as would constitute a clearly unwarranted This invention is a microscopy device and system for multi-photon amended (5 U.S.C. App.), notice is invasion of personal privacy. hereby given of the following meeting. microscopy utilizing multi-view Name of Committee: National Institute of nonlinear optical imaging. Nonlinear The meeting will be closed to the Allergy and Infectious Diseases Special public in accordance with the Emphasis Panel. optical imaging remains the premier technique for deep-tissue imaging in provisions set forth in sections Date: July 27, 2016. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Time: 2:00 p.m. to 5:00 p.m. which typically a multi photon arrangement may be used to illuminate as amended. The grant applications and Agenda: To review and evaluate grant applications. and excite a sample. However, the the discussions could disclose Place: National Institutes of Health, 5601 penetration depth, signal-to-noise ratio, confidential trade secrets or commercial Fishers Lane, Rockville, MD 20892, and resolution of this technique is property such as patentable material, (Telephone Conference Call). ultimately limited by scattering. The and personal information concerning Contact Person: James T. Snyder, Ph.D., present system addresses these issues by individuals associated with the grant mstockstill on DSK3G9T082PROD with NOTICES Scientific Review Officer, Scientific Review applications, the disclosure of which Program, Division of Extramural Activities/ sequential excitation of a sample through three or more objective lenses would constitute a clearly unwarranted Room 3G31B, National Institutes of Health, invasion of personal privacy. NIAID, 5601 Fishers Lane MSC 9823, oriented at different axes intersecting Bethesda, MD 20892–9823, (240) 669–5060, the sample. Each objective lens is Name of Committee: National Cancer james.snyder@nih.gov. capable of focused sequential excitation Institute Special Emphasis Panel; Member (Catalogue of Federal Domestic Assistance that elicits fluorescence emissions from Conflict SEP. Program Nos. 93.855, Allergy, Immunology, the excited sample, which is then Date: July 6, 2016. VerDate Sep<11>2014 20:01 Jun 29, 2016 Jkt 238001 PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 E:\FR\FM\30JNN1.SGM 30JNN1

42720 Federal Register / Vol. 81, No. 126 / Thursday, June 30, 2016 / Notices Time: 10:30 a.m. to 3:00 p.m. published in the Federal Register HHS-Certified Laboratories Agenda: To review and evaluate grant during the first week of each month. If applications. ACM Medical Laboratory, Inc., 160 any laboratory or IITF certification is Elmgrove Park, Rochester, NY 14624, Place: National Cancer Institute Shady suspended or revoked, the laboratory or 585–429–2264 Grove, 9609 Medical Center Drive, Room 7W602, Rockville, MD 20850, (Telephone IITF will be omitted from subsequent Aegis Analytical Laboratories, Inc., 345 Conference Call). lists until such time as it is restored to Hill Ave., Nashville, TN 37210, 615– Contact Person: Delia Tang, MD, Scientific full certification under the Mandatory 255–2400, (Formerly: Aegis Sciences Review Officer, Research Programs Review Guidelines. Corporation, Aegis Analytical Branch, Division of Extramural Activities, If any laboratory or IITF has Laboratories, Inc., Aegis Analytical National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, MD withdrawn from the HHS National Laboratories) 20850 240–276–7684, tangd@mail.nih.gov. Laboratory Certification Program (NLCP) Alere Toxicology Services, 1111 Newton during the past month, it will be listed St., Gretna, LA 70053, 504–361–8989/ This notice is being published less than 15 days prior to the meeting due to the timing at the end and will be omitted from the 800–433–3823, (Formerly: Kroll limitations imposed by the review and monthly listing thereafter. Laboratory Specialists, Inc., funding cycle. This notice is also available on the Laboratory Specialists, Inc.) (Catalogue of Federal Domestic Assistance Internet at http://www.samhsa.gov/ Alere Toxicology Services, 450 Program Nos. 93.392, Cancer Construction; workplace. Southlake Blvd., Richmond, VA 93.393, Cancer Cause and Prevention 23236, 804–378–9130, (Formerly: Research; 93.394, Cancer Detection and FOR FURTHER INFORMATION CONTACT: Kroll Laboratory Specialists, Inc., Diagnosis Research; 93.395, Cancer Giselle Hersh, Division of Workplace Scientific Testing Laboratories, Inc.; Treatment Research; 93.396, Cancer Biology Programs, SAMHSA/CSAP, 5600 Kroll Scientific Testing Laboratories, Research; 93.397, Cancer Centers Support; Inc.) Fishers Lane, Room 16N03A, Rockville, 93.398, Cancer Research Manpower; 93.399, Baptist Medical Center—Toxicology Cancer Control, National Institutes of Health, Maryland 20857; 240–276–2600 (voice). HHS) Laboratory, 11401 I–30, Little Rock, SUPPLEMENTARY INFORMATION: The AR 72209–7056, 501–202–2783, Dated: June 24, 2016. Mandatory Guidelines were initially (Formerly: Forensic Toxicology Melanie J. Gray, developed in accordance with Executive Laboratory Baptist Medical Center) Program Analyst, Office of Federal Advisory Order 12564 and section 503 of Public Clinical Reference Lab, 8433 Quivira Committee Policy. Law 100–71. The ‘‘Mandatory Road, Lenexa, KS 66215–2802, 800– [FR Doc. 2016–15447 Filed 6–29–16; 8:45 am] Guidelines for Federal Workplace Drug 445–6917 BILLING CODE 4140–01–P Testing Programs,’’ as amended in the DrugScan, Inc., 200 Precision Road, revisions listed above, requires strict Suite 200, Horsham, PA 19044, 800– standards that laboratories and IITFs 235–4890 DEPARTMENT OF HEALTH AND must meet in order to conduct drug and Dynacare*, 245 Pall Mall Street, HUMAN SERVICES specimen validity tests on urine London, ONT, Canada N6A 1P4, 519– specimens for federal agencies. 679–1630, (Formerly: Gamma- Substance Abuse and Mental Health To become certified, an applicant Dynacare Medical Laboratories) Services Administration laboratory or IITF must undergo three ElSohly Laboratories, Inc., 5 Industrial rounds of performance testing plus an Park Drive, Oxford, MS 38655, 662– Current List of HHS-Certified on-site inspection. To maintain that 236–2609 Laboratories and Instrumented Initial certification, a laboratory or IITF must Fortes Laboratories, Inc., 25749 SW Testing Facilities Which Meet Minimum participate in a quarterly performance Canyon Creek Road, Suite 600, Standards To Engage in Urine Drug testing program plus undergo periodic, Wilsonville, OR 97070, 503–486–1023 Testing for Federal Agencies on-site inspections. Laboratory Corporation of America AGENCY: Substance Abuse and Mental Laboratories and IITFs in the Holdings, 7207 N. Gessner Road, Health Services Administration, HHS applicant stage of certification are not to Houston, TX 77040, 713–856–8288/ ACTION: Notice be considered as meeting the minimum 800–800–2387 requirements described in the HHS Laboratory Corporation of America SUMMARY: The Department of Health and Mandatory Guidelines. A HHS-certified Holdings, 69 First Ave., Raritan, NJ Human Services (HHS) notifies federal laboratory or IITF must have its letter of 08869, 908–526–2400/800–437–4986, agencies of the laboratories and certification from HHS/SAMHSA (Formerly: Roche Biomedical Instrumented Initial Testing Facilities (formerly: HHS/NIDA), which attests Laboratories, Inc.) (IITF) currently certified to meet the that it has met minimum standards. Laboratory Corporation of America standards of the Mandatory Guidelines Holdings, 1904 Alexander Drive, for Federal Workplace Drug Testing In accordance with the Mandatory Research Triangle Park, NC 27709, Programs (Mandatory Guidelines). The Guidelines dated November 25, 2008 919–572–6900/800–833–3984, Mandatory Guidelines were first (73 FR 71858), the following HHS- (Formerly: LabCorp Occupational published in the Federal Register on certified laboratories and IITFs meet the Testing Services, Inc., CompuChem April 11, 1988 (53 FR 11970), and minimum standards to conduct drug Laboratories, Inc.; CompuChem subsequently revised in the Federal and specimen validity tests on urine Laboratories, Inc., A Subsidiary of Register on June 9, 1994 (59 FR 29908); specimens: Roche Biomedical Laboratory; Roche mstockstill on DSK3G9T082PROD with NOTICES September 30, 1997 (62 FR 51118); HHS-Certified Instrumented Initial CompuChem Laboratories, Inc., A April 13, 2004 (69 FR 19644); November Testing Facilities Member of the Roche Group) 25, 2008 (73 FR 71858); December 10, Laboratory Corporation of America 2008 (73 FR 75122); and on April 30, Dynacare, 6628 50th Street NW., Holdings, 1120 Main Street, 2010 (75 FR 22809). Edmonton, AB Canada T6B 2N7, 780– Southaven, MS 38671, 866–827–8042/ A notice listing all currently HHS- 784–1190, (Formerly: Gamma- 800–233–6339, (Formerly: LabCorp certified laboratories and IITFs is Dynacare Medical Laboratories) Occupational Testing Services, Inc.; VerDate Sep<11>2014 20:01 Jun 29, 2016 Jkt 238001 PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 E:\FR\FM\30JNN1.SGM 30JNN1


Document Created: 2018-02-08 07:45:34
Document Modified: 2018-02-08 07:45:34
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesJuly 6, 2016.
FR Citation81 FR 42719 
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR